Technology
All of our product candidates that are currently in clinical trials, preclinical testing and earlier stages of discovery were discovered using our proprietary drug discovery platform. We believe that our expertise combined with our proprietary platform has allowed us to discover product candidates more efficiently than traditional approaches. Our proprietary drug discovery platform combines target-based and chemistry-based technologies to enable efficient discovery of new compounds that may serve as potential treatments for significant unmet medical needs.
We have developed proprietary target-based platforms to screen G-protein coupled receptors, nuclear receptors, and tyrosine kinase linked receptors, some of the most relevant and feasible targets for small molecule discovery. These platforms allow us to profile our collection of reference drugs over the range of targets to link clinical and physiological effects of drugs with specific drug targets. We have assembled a large proprietary chemical library of diverse compounds. This diverse compound library consists of about 800,000 small organic molecules. We have also developed proprietary synthetic methods for library construction and lead optimization. Our drug discovery approach aims to identify small molecules that can serve as chemical starting points, or leads, for optimization efforts providing novel, potent and selective product candidates for targets that are most likely to be affected by small molecule drugs.
Our research facilities are located in San Diego, California and Malmo, Sweden.
back to top